A carregar...
Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: emphasis on ponatinib
The advent of tyrosine kinase inhibitors (TKIs) targeted therapy revolutionized the treatment of chronic myeloid leukemia (CML) patients. However, cardiotoxicity associated with these targeted therapies puts the cancer survivors at higher risk. Ponatinib is a third-generation TKI for the treatment o...
Na minha lista:
| Publicado no: | Int J Cardiol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8095092/ https://ncbi.nlm.nih.gov/pubmed/32470534 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijcard.2020.05.077 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|